Clinical/Translational Aspects of Advanced Glycation End-Products

Chang Zeng, Yuanyuan Li, Jingzhi Ma, Lina Niu, Franklin R. Tay

Research output: Contribution to journalReview article

Abstract

Advanced glycation end-products (AGEs) have been implicated in chronic hyperglycemia and age-related diseases. Endogenous AGEs produced by humans generate oxidative stress and activation of inflammatory signaling pathways via AGE-specific receptors. The present review summarizes current knowledge on the pathogenic role of AGEs in chronic noncommunicable diseases. Although correlations exist between glycation and the pathogenesis of these diseases, uncertainties remain in light of recurrent intervention failures of apparently promising animal models to be translated into clinically useful anti-AGE strategies. Future intervention of AGEs or their receptors should embrace more carefully executed clinical trials. Nevertheless, suppressing symptoms via lifetime drug application is unlikely to eliminate the burden of chronic diseases unless deep-rooted lifestyle issues that cause these diseases are simultaneously addressed.

Original languageEnglish (US)
Pages (from-to)959-973
Number of pages15
JournalTrends in Endocrinology and Metabolism
Volume30
Issue number12
DOIs
Publication statusPublished - Dec 2019

    Fingerprint

Keywords

  • advanced glycation end-products
  • chronic diseases
  • glycation
  • lifestyle
  • receptor for advanced glycation end-products
  • α-dicarbonyls

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this